Project Grant R50CA285412
Award Date
9/4/24
Completion Date
8/31/29
Dollars Obligated
$196K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
The University of California, Irvine was awarded a $2,186,372 five-year Project Grant under the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program. The grant, titled "Tipping Points in Cancer", will address fundamental questions about cancer initiation and progression through three team-oriented research projects. The projects will investigate cell states, cell-cell interactions, and non-genetic transitions that drive the progression from pre-malignant to...
This $135,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the following key objectives at the University of Virginia Comprehensive Cancer Center (UVA): Increase UVA's accrual depth and breadth in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) clinical trials by identifying and overcoming provider and patient barriers. Increase UVA's leadership and collaboration in...
This National Cancer Institute (NCI) Project Grant award under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program provides $408,913 to the University of California Irvine from August 15, 2024 to July 31, 2029. The project investigates the mechanisms by which genes encoding ribosomal proteins are used as sensors for altered cellular chromosome content in fruit flies, a genetic model system. The research aims to define the molecular basis for cellular recognition and...
This $172,197 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish and refine processes to facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). Key objectives include: Hiring project navigators to support study approvals for principal investigators in non-oncology departments outside KUCC Training research coordinators in cancer prevention trial processes...
The National Cancer Institute (NCI) awarded a $148,568 Project Grant to The Leland Stanford Junior University (Stanford University) under the NCI's Cancer Research Manpower (CFDA 93.398) program. The grant, which runs from December 17, 2024 to July 14, 2027, supports research to integrate highly multiplexed immunofluorescence with label-free 2D hyperspectral chemical imaging to interrogate the colorectal cancer tumor-invasive front. This innovative approach aims to enhance the understanding of...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
This National Cancer Institute (NCI) Project Grant award, under the Cancer Research Manpower (CFDA 93.398) program, provides $128,509.00 to the University of California, Los Angeles (UCLA) from April 1, 2025 to March 31, 2027. The award supports the development of "TreatMonitor", a computational system for ultrasensitive, comprehensive, and affordable cancer monitoring using multi-omics profiling of cell-free DNA (cfDNA). The project aims to improve minimal residual disease (MRD) and...
The National Cancer Institute (NCI) awarded a $224,099 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The key objectives are to: 1) characterize the acceptability and factors influencing CRC screening uptake in this newly eligible age group, and 2) evaluate the comparative effectiveness of an active outreach screening approach versus...
This federal Project Grant award for $194,778 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the optimization of strategies to improve NCI-sponsored clinical trial participation across the Weill Cornell Medicine - Meyer Cancer Center sphere, which serves a diverse population of approximately 6 million patients in the New York City metropolitan area. The principal investigator, Dr. Tagawa, has extensive experience leading and mentoring others on NCI clinical...
The National Cancer Institute (NCI) awarded a $566,523 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Colorado-Denver. The 5-year grant, awarded on Dec 5, 2024, will fund research to identify interception targets in persistent lung pre-malignant lesions (PMLs) and determine the effects of prevention agents on persistence pathways. The research aims to develop a precision approach for lung cancer prevention by intercepting PMLs most...